Novo Nordisk shares fall on weight loss drug trial

Shares of Novo Nordisk After trading Monday morning, the company announced the results of its last weight drug experience.

The results of Novo’s results in the last stages of Hagisemia were held in the last stage of Haghisema that patients with the highest dose of the drug lost 15.7% of their weight. According to the data, according to the data, the patients are lost, lost 3.1%.

The trial included 1,206 people, who has an obesity or overweight listener and listen to type 2 diabetes. They had a middle initial body weight of about 224 pounds.

The shares of Denmark’s pharmaceutical giant have fallen more than 9% when the company released results.

Wall Street looked at the results of the trial to see how the drug was compared to the company’s other drugs, Ozzemp, and Wegovy is confirmed for chronic weight management.

Eli Lilly’s Zepbound Reduces Type 2 Diabetes Risk, Shaws

In December, the company saw its market value for $ 125 billion, after a separate trial, RedeFine 1 from Cagrisema overweight or obese patients Without type 2 diabetes.

The head office of the pharmaceutical company in Copenhagen, Denmark, on September 26, 2023. (Tom Small / File Photo / Reuters Photos)

During the last trial of 68 weeks, 61.9% of patients were given the highest dose of the drug, which combines the active component of Wegovy and Ozempic, and CagrilIlide with synthetic version of Hormone Amylin.

Ozempic, Wegovy among drugs that are subject to Medicare Prices Control

Cresgrilintide is currently being developed together with Semaglutide to see if it helps overweight and obesity loss of heavy weight loss.

Novo said that he would present in detail the results of the two trials, which will be presented in 2025. At the scientific conference and expect to submit the first regulatory approval of Cagrisema in the first quarter of the fiscal year.

Wegovy is a prescription for weight loss prescription that helped people with obesity. (Michael Siluk / UCG / Universal Images Group Via / Getty Images)

“The two renewable results confirmed the high quality efficiency of cagrisema in the 2nd diabetes with excess or obese,” said Martin Holst Lang. “We expect to bring this second key trial regulatory bodies to make this next generation therapy available to millions of patients in need.”

Novo Nordisk and Eli Lilly walk around their proposals and create direct consumer platforms without insurance to promote the demand as a high profitable market.

Get Fox Business Go by clicking here

Novo’s revenues have exceeded the expectations of Wall Street in its latest financial quarter, but predicts growth in a slower sale in 2025, in part due to the growth of competition.

Nouvo cut its value last week Blockbuster’s weight loss drug Wegovy halves half-half, pays cash through its immediate patient online pharmacy to try and promote sales.

The company’s statement came to declare Lille that it expands its weight loss drug supply and cut again, again expanding access to more patients.

Reuters contributed to this report.